Friday, Jun 12, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Science & Tech | Pfizer Moderna Vaccines Cut Infection Risk By 91 Us Cdc

Pfizer, Moderna vaccines cut infection risk by 91%: US CDC

Even a single dose of the mRNA vaccines can reduce the risk of infection by 81 per cent. These estimates included symptomatic and asymptomatic infections.

By IANS
Published Date - 8 June 2021, 12:05 PM
Pfizer, Moderna vaccines cut infection risk by 91%: US CDC
Representational Image.
whatsapp facebook twitter telegram

Washington: Taking two doses of the Pfizer-BioNTech and Moderna’s mRNA-based vaccines, authorised by the Food and Drug Administration, can reduce the risk of coronavirus infection by 91 per cent, according to a new study by the US Centers for Disease Control and Prevention (CDC).

Even a single dose of the mRNA vaccines can reduce the risk of infection by 81 per cent. These estimates included symptomatic and asymptomatic infections.


“Covid-19 vaccines are a critical tool in overcoming this pandemic,” said CDC Director Rochelle P Walensky.

“Findings from the extended timeframe of this study add to accumulating evidence that mRNA Covid-19 vaccines are effective and should prevent most infections — but that fully vaccinated people who still get Covid-19 are likely to have milder, shorter illness and appear to be less likely to spread the virus to others. These benefits are another important reason to get vaccinated,” Walensky added.

The study also showed that mRNA vaccination benefits people who get Covid-19 despite being fully vaccinated (14 or more days after dose 2) or partially vaccinated (14 or more days after dose 1 to 13 days after dose 2).

Fully or partially vaccinated people who developed Covid-19 spent on average six fewer total days sick and two fewer days sick in bed. They also had about a 60 per cent lower risk of developing symptoms, like fever or chills, compared to those who were unvaccinated. Some study participants infected with SARS-CoV-2 did not develop symptoms.

People who were fully or partially vaccinated and then got Covid-19 had 40 per cent less detectable virus in their nose (that is, a lower viral load), and the virus was detected for six fewer days (that is, viral shedding) compared to those who were unvaccinated when infected. This means they were also less likely to spread the virus to others.

In addition, people who were partially or fully vaccinated were 66 per cent less likely to test positive for SARS-CoV-2 infection for more than one week compared to those who were unvaccinated.

While these indicators are not a direct measure of a person’s ability to spread the virus, they have been correlated with reduced spread of other viruses, such as varicella and influenza, the CDC said.

For the study, 3,975 participants completed weekly SARS-CoV-2 testing for 17 consecutive weeks (from December 13, 2020 to April 10, 2021) in eight US locations.

Participants self-collected nasal swabs that were laboratory tested for SARS-CoV-2. If the tests came back positive, the specimens were further tested to determine the amount of viral load and viral shedding.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

  • Follow Us :
  • Tags
  • Moderna vaccine
  • Pfizer-BioNTech Covid-19 vaccine
  • risk of coronavirus infection
  • US Centers for Disease Control and Prevention (CDC)

Related News

  • Granules India Limited’s ANDA for Esomeprazole Magnesium Delayed-Release Capsules USP approved

    Granules India Limited’s ANDA for Esomeprazole Magnesium Delayed-Release Capsules USP approved

  • Neuralink receives FDA approval for first-in-human clinical study

    Neuralink receives FDA approval for first-in-human clinical study

  • US CDC panel endorses Pfizer booster shot for elderly, high-risk people

    US CDC panel endorses Pfizer booster shot for elderly, high-risk people

  • Pfizer, Moderna vaccines cut COVID-19 risk by 91 per cent: Study

    Pfizer, Moderna vaccines cut COVID-19 risk by 91 per cent: Study

Latest News

  • Editorial: Agonising wait for AI crash probe report 

    7 mins ago
  • Revanth’s flight diverted to Bengaluru amid heavy rains in Hyderabad

    8 mins ago
  • Rajnath Singh urges DRDO to develop futuristic defence technologies

    37 mins ago
  • Watch: Dhamaal 4 trailer promises laughter-packed treasure hunt

    42 mins ago
  • First batch of Kailash Mansarovar Yatra pilgrims to reach Sikkim on June 15

    1 hour ago
  • Totally unacceptable: Trump condemns alleged Iran attack on Indian vessels

    1 hour ago
  • SEBI reviews short-selling framework, plans AI guidelines to deepen capital markets

    1 hour ago
  • Revanth alleges BJP role in Meenakshi Natarajan nomination row, targets Kishan Reddy

    2 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam